

Supplemental data

Table S1 Therapeutic regimens used for treatment of the examined breast carcinoma patient sets.

Therapy regimen	Adjuvant set	Neoadjuvant set
Neoadjuvant chemotherapy	None	
FAC (Fluorouracil+Adriamycin+Cyclophosphamide) or FEC (Fluorouracil+Epirubicine+Cyclophosphamide)		24 (35.6)
Adriamycin and Taxane (Taxotere/Taxol)		28 (11.9)
Taxane only		1 (1.7)
Hormonal therapy (Tamoxifen or aromatase inhibitors)		3 (5.1)
Other ^a		3 (5.1)
Adjuvant chemotherapy ^b		
FAC or FEC	9 (20.5)	2 (3.4)
Adriamycin and Taxane	1 (2.3)	2 (3.4)
Taxane only	0	35 (59.3)
Hormonal therapy	27 (61.4)	16 (27.1)
Other ^c	3 (6.8)	4 (6.8)
Data not available	4 (9.0)	0

^aOther therapeutic neoadjuvant regimens involved adriamycin+cyclophosphamide combination (n=2) and paclitaxel+estramustine+carboplatin (TEC) regimen (n=1); ^bAdjuvantly used cytostatics were followed by hormonal treatment in five cases. Patients receiving only hormonal therapy are listed under Hormonal therapy; ^cOther therapeutic regimens included cyclophosphamide+methotrexate+5-fluorouracil (CMF) regimen (n=2), Adriamycin+cyclophosphamide (n=2), farmorubicin+paxene (n=1) and hormonal therapy using Zoladex (n=1). One patient was not treated by any adjuvant chemotherapy regimen. Three patients received Herceptin in the course of adjuvant therapy.

Table S2 Clinico-pathological characteristics of examined breast cancer patients.

Characteristics	Adjuvant set ^a	Neoadjuvant set ^a
Median age at diagnosis, years±standard deviation	64.2±10.4	54.7±9.1
Menopausal status		
Premenopausal	6 (13.6)	22 (37.3)
Postmenopausal	38 (86.4)	37 (62.7)
Family anamnesis		
Positive	17 (38.6)	16 (27.1)
Negative	27 (61.4)	43 (72.9)
Not available	0	3
Stage		
0	0 (0)	2 (3.4)
I	18 (40.9)	18 (30.5)
II	20 (45.5)	30 (50.8)
III	3 (6.8)	7 (11.9)
Not available	3	2
Average tumor size, mm±standard deviation	16.1±11.0	30.8±11.6
Nodal status		
Positive (N1-3)	17 (47.9)	24 (62.5)
Negative (N0)	24 (52.1)	34 (37.5)
Nx	3	1
Histological type		
Invasive duct carcinoma	36 (81.8)	53 (89.8)
Other type ^b	8 (18.2)	6 (10.2)
Histological grade		
1	7 (15.9)	8 (13.6)
2	32 (72.7)	23 (39.0)
3	4 (9.1)	25 (42.4)
Not available	1	3
Estrogen receptor status		
Positive	36 (81.8)	41 (69.5)
Negative	8 (18.2)	18 (30.5)
Progesterone receptor status		
Positive	31 (70.5)	42 (71.2)
Negative	13 (29.5)	17 (28.8)
HER2 status		
Positive	30 (68.2)	40 (67.8)
Negative	14 (31.8)	19 (32.2)
p53 status		
Positive	5 (11.4)	
Negative	35 (79.5)	
Not available	4	59
Ki67 status		
Ki67 >20%		35 (59.3)
Ki67 <20%		19 (32.2)
Not available	44	5

^aNumber of patients with percentage in parentheses is shown; ^bOther tumor types (in adjuvant/neoadjuvant set) involved invasive lobular (6/4), mucinous (1/1), medullary (0/1) and comedo (1/0) carcinomas.




Figure S1 Evaluation of *ABCB1* SNPs (rs2214102, rs1128503, rs2032582, rs2032583 and rs1045642) using direct sequencing.




Figure S2 Melting curves of rs2032582 GG homozygote (A) and GT heterozygote (B) genotypes in the presence of rs2032583 SNP detected by HRM analysis.

(A) 2677G>T/A variations GG (bright green curves) and G.G with variation in 183941 position (dark green curves). (B) 2677G>T/A variations GT (pink curves) and GT with variation in 183941 position (violet curves).